BIO applauds PERA and PREVAIL patent reform bills
BIO applauds the PERA Act to clarify court decisions on patents and the PREVAIL Act to limit abuses by patent challengers.| Bio.News
BIO applauds the PERA Act to clarify court decisions on patents and the PREVAIL Act to limit abuses by patent challengers.| Bio.News
On the state level, patients are seeing an increasing number of barriers that are making it harder for them to access the therapies they […] The post September Coffee Chat: The State of Patient Access appeared first on Bio.News.| Bio.News
For much of Maia’s life, she didn’t talk about her sickle cell disease, yet as she grew into her healthcare career, and became more […] The post Sick Cells: Elevating the patient voice appeared first on Bio.News.| Bio.News
The Patent Eligibility Restoration Act (PERA) would support innovation by clarifying what kind of ideas can be patented, Senators agreed.| Bio.News
Arthritis is the #1 cause of disability in the U.S., affecting 1 in 4 adults. And while arthritis is typically considered to be an […] The post World Arthritis Day: Anyone can be an advocacy hero appeared first on Bio.News.| Bio.News
BIO explored the biotech ecosystem of Illinois, where expertise, manufacturing, and state support make biotech a growing source of jobs.| Bio.News
Not many people know what amyloidosis is, and for Mike Lane, Founder of the Amyloidosis Army, that’s a problem he wants to change. “That’s […] The post Amyloidosis: Under-diagnosed disorder with serious consequences appeared first on Bio.News.| Bio.News
European countries don’t just pull prices for medicines out of thin air. The prices that those governments set are based on specific sets of […] The post Putting Americans First: Importing European prices means importing European systems and values appeared first on Bio.News.| Bio.News
The rapidly growing biotech ecosystem supporting innovation in Texas received national attention during a visit by BIO on Sept. 15-16.| Bio.News
It is often taken as a given that drug prices in the U.S. are higher than those in other nations. And while there is […] The post Putting Americans First: International prices in context appeared first on Bio.News.| Bio.News
Already providing employment for 129,245 people and $95 billion in annual economic output, Texas’s biotech sector is growing rapidly. That sector will be highlighted […] The post BIO’s Texas visit will highlight a growing biotech ecosystem appeared first on Bio.News.| Bio.News
In the three years since the Inflation Reduction Act (IRA) was signed into law, there arenegative impacts on patient access, advocates say.| Bio.News
Riboway Therapeutics, 2025 BIO Start-Up Stadium winner, decodes hidden RNA events to enable drugging targets once thought impossible.| Bio.News
Bio.News spoke with the National Psoriasis Foundation to discuss federal and local action toward patient-centered psoriatic disease care.| Bio.News
Biotech firms weighing an IPO must consider timing, interest in their product, and macro environment said a BIO Investor Forum panel.| Bio.News
BIO's 2025 report on the state of emerging biotechs finds that the landscape is challenging, though opportunities exist.| Bio.News
Bio.News is a daily news website exploring the wonders of biotechnology and the intersection of biotech innovation and U.S. and international policy.| Bio.News
What are biomarkers, and why do they matter? Dr. Colleen Pietras, M.D., explains why biomarkers matter to patients and drug development.| Bio.News
Keep up with the latest global discoveries, top experts and panelists at BIO International Convention.| Bio.News
Learn about BIO's views and positions on topics such as bioeconomy, biofuels and healthcare.| Bio.News
New political uncertainty could pose challenges for a slowly improving biotech M&A market, said panelists at BIO CEO 2025.| Bio.News
The idea of AI supercharging drug development is stirring a lot of excitement. However, a realistic understanding of what AI can and can’t do […]| Bio.News
PBMs make billions while driving up the price of drugs with markups that can exceed 1,000%, according to an FTC report released Jan. 14.| Bio.News
The accelerated approval pathway provides incredible benefit to patients with serious unmet medical need, and there’s data to back it up.| Bio.News
The Centers for Medicare & Medicaid Services (CMS) issued a directive telling private insurers providing Medicare Advantage (MA) plans to cover Biogen’s amyotrophic lateral sclerosis […]| Bio.News
The U.S. bioscience industry generated $3.2 trillion in output in 2023, according to a report from BIO and CSBA in partnership with TEConomy.| Bio.News
FTC released an interim report criticizing the negative impact pharmacy benefit manager (PBMs) have on prescription drug prices and access.| Bio.News
PBM industry that has driven reimbursement so low as to threaten the viability of local community pharmacies.| Bio.News
Rather than incentivizing PBMs to seek out medicines with high prices, there is a movement to “delink” price and PBM compensation.| Bio.News
BIO shares its strategic priorities to improve policy that impacts biotechnology and to foster an ecosystem where innovation can thrive.| Bio.News
PBMs save money with “step therapy,” which tries to displace a provider’s clinical judgment in favor of the medicine selected by the PBM.| Bio.News
